<span item_type="fundamental" item_id="0ad31b163a14cec8dbb82e85e7b26d3b" counter_id="ST/US/ENVB" env="prod"></span><span item_type="announcement" item_id="648614173607658753" env="prod"></span><p>EPS: As of FY2026 Q1, the actual value is USD -1.08.</p><p></p><h4>Net Loss</h4><p>Enveric Biosciences, Inc. reported a net loss attributable to stockholders of - $1.6 million for the first quarter ended March 31, 2026, which included - $0.1 million in net non-cash expense. This compares to a net loss of - $2.2 million for the quarter ended March 31, 2025, which included $0.3 million in net non-cash income. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm"></span></p><h4>Cash Position</h4><p>As of March 31, 2026, Enveric Biosciences, Inc. had cash-on-hand of $4.9 million. As of May 15, 2026, the company’s cash balance was approximately $10.3 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm"></span></p><h4>Capital Raises</h4><p>During the first quarter of 2026, Enveric Biosciences, Inc. raised gross proceeds of $2.8 million through offerings, including approximately $1.5 million from a registered direct offering. Subsequent to the first quarter, the company raised an additional approximately $1.5 million from the exercise of warrants. Enveric Biosciences, Inc. also closed a private placement expected to generate gross proceeds of up to $13.9 million, including $5 million received upfront and approximately $8.9 million in potential additional proceeds upon full exercise of warrants. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm"></span></p><h4>Operational Highlights</h4><p><strong>Product Development:</strong> Enveric Biosciences, Inc. continued the advancement of its lead candidate EB-003, with IND-enabling studies progressing toward a planned first-in-human clinical trial. Additional preclinical data for EB-003 demonstrated dual Gq and β-arrestin signaling at 5-HT2A. Subsequent to the first quarter, positive results for EB-003 highlighted a rapid reduction in conditioned fear response in a preclinical model of PTSD. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm"></span></p><p><strong>Intellectual Property:</strong> The company strengthened its intellectual property portfolio with new patent issuances and allowances across its EVM301 and EVM401 series. AbbVie, Inc. withdrew a Post-Grant Review petition filed against Enveric Biosciences, Inc.’s U.S. Patent No. 12,138,276. Enveric Biosciences, Inc. also enhanced patent claim coverage for its N-heterocycle substituted tryptamine derivative molecules for non-hallucinogenic treatment of neuropsychiatric conditions. Five of its trademarks, including Enveric and Enveric Biosciences, were registered with the Canadian Intellectual Property Office. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm"></span></p><p><strong>Corporate &amp; Business Development:</strong> Enveric Biosciences, Inc. participated in a panel discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum. The company expanded its collaboration with TOTEC Pharma through a trademark license and option, out-licensing the RCANN™ trademark portfolio. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm"></span></p><h4>Outlook</h4><p>Enveric Biosciences, Inc. anticipates that its current funds will support the completion of preclinical development activities for EB-003, the planned filing of an IND application, and operations into the first quarter of fiscal year 2027. The company remains focused on advancing EB-003 towards an IND submission and first-in-human clinical trials. Enveric Biosciences, Inc. believes it is well positioned to generate meaningful value for stockholders as it transitions toward the clinical phase of drug development. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/ex99-1.htm"></span></p>

Enveric Biosciences | 8-K: FY2026 Q1 EPS: USD -1.08